Adam Fine is a co-founder and CEO of Windham Venture Partners. Adam is currently Director at GlySens, CuraSeal and HelpAround, Board Observer to SpineView, MC10, Holaira and VytronUS. Adam is a mentor in Blueprint Health, a healthcare IT accelerator in NYC. Prior to Windham, Adam was VP & GM at I-many, Inc., an enterprise software company.. Prior to joining I-many, Adam was a New Business Development Analyst at Cordis Corporation, a Johnson & Johnson company focused on interventional vascular devices such as stents. In that capacity, Adam worked on a range of licenses, acquisitions, divestments, as well as strategic investments with Johnson & Johnson Development Corporation (JJDC), J&J’s strategic venture arm. Prior to J&J, Adam was a research analyst at Coopers & Lybrand’s Integrated Healthcare Consulting practice.
